EC ducks action on drug prices
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.THE European Commission yesterday drew back from pushing for action on pharmaceutical price controls, to the surprise of industry representatives.
A final Commission document outlining a new policy for the industry was less forceful than earlier drafts on what some parts of the industry considered the crucial issue, state-administered price controls.
'We would have liked it to be tougher,' said Marie-Claire Pickaert, an official of the European Federation of Pharmaceutical Industry Associations. 'I am aghast,' said an industry source. 'To create a single market requires that price controls be either harmonised or reduced.'
Commission officials argue that direct price controls are not at the heart of the industry's problems, that the Commission lacks the legal competence to tackle them, and there are plenty of other issues that need tackling.
'This is a much more sophisticated and pragmatic document than earlier drafts,' said one official, who added that it was unlikely health ministers would have accepted an onslaught on price controls.
The report avoids measures to remove or harmonise direct price controls on pharmaceutical products, which are applied by member states to reduce healthcare budgets.
Some companies argue that price controls in some states restrict their ability to charge market prices for products that have required large- scale research and development costs. Furthermore, since the EU prevents countries from banning imports, low-cost drugs enter markets with looser price controls, bringing prices down, they argue.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments